Citius Pharmaceuticals Inc
For the period ended Sep 30, 2024. Filed Dec 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Dec 27, 2024
CTXR$0.49-6.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
| 2024 · 2023 | |||
|---|---|---|---|
| Cash Flows From Operating Activities: | |||
| Net loss | $(39,425,839) | $(32,542,912) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Stock-based compensation | 11,839,678 | 6,616,705 | |
| Issuance of common stock for services | 284,176 | 102,000 | |
| Amortization of operating lease right-of-use asset | 208,179 | 191,648 | |
| Depreciation | 1,432 | 2,668 | |
| Deferred income tax expense | 576,000 | 576,000 | |
| Changes in operating assets and liabilities: | |||
| Inventory | (2,133,871) | - | |
| Prepaid expenses | (945,389) | (5,036,926) | |
| Accounts payable | 1,999,877 | 1,761,956 | |
| Accrued expenses | (459,273) | (929,094) | |
| Accrued compensation | 72,035 | 394,732 | |
| Operating lease liability | (218,380) | (196,989) | |
| Net Cash Used In Operating Activities | (28,201,375) | (29,060,212) | |
| Cash Flows From Investing Activities: | |||
| License payment | (5,000,000) | - | |
| Net Cash Used In Investing Activities | (5,000,000) | - | |
| Cash Flows From Financing Activities: | |||
| Proceeds from common stock option exercises | - | 31,267 | |
| Merger, net | (3,831,357) | ||
| Net proceeds from registered direct offerings | 13,803,684 | 13,798,183 | |
| Net Cash Provided By Financing Activities | 9,972,327 | 13,829,450 | |
| Net Change in Cash and Cash Equivalents | (23,229,048) | (15,230,762) | |
| Cash and Cash Equivalents – Beginning of Year | 26,480,928 | 41,711,690 | |
| Cash and Cash Equivalents – End of Year | $3,251,880 | $26,480,928 | |
| Supplemental Disclosures of Cash Flow Information and Non-cash Activities: | |||
| IPR&D Milestones included in License Payable | $28,400,000 | $ | - |
| Prepaid Manufacturing transferred to Inventory | $6,134,895 | $ | - |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.